# The tumor microenvironment shapes gastric cancer progression by coordinating immune suppression and metabolic reprogramming

**Authors:** Fuzhi Jiao, Zhen Wang, Jing Yuan, Fenglei Shi, Shengnan Zhang

PMC · DOI: 10.3389/fimmu.2026.1787060 · 2026-03-11

## TL;DR

This paper reviews how the tumor microenvironment in gastric cancer promotes cancer progression through immune suppression and metabolic changes.

## Contribution

The paper provides a comprehensive overview of the bidirectional interactions between gastric cancer cells and the tumor microenvironment.

## Key findings

- The tumor microenvironment supports immune evasion through regulatory T cells and macrophages.
- Metabolic reprogramming in gastric cancer includes glycolysis and altered lipid metabolism.
- ECM remodeling and signaling pathways like PI3K/AKT/mTOR and TGF-β drive cancer progression.

## Abstract

Gastric cancer (GC) remains a leading cause of cancer mortality, largely owing to metastasis driven by a highly dynamic tumor microenvironment (TME). Immunosuppressive regulatory T cells (Tregs) and tumor-associated macrophages (TAMs) orchestrate immune evasion through checkpoint signaling and polarization programs, while cancer-associated fibroblasts (CAFs) reshape stromal architecture and promote hypoxia. Concurrently, ECM remodeling—mediated by integrins, growth factors, and matrix metalloproteinases—activates oncogenic pathways such as PI3K/AKT/mTOR, MAPK/ERK, and TGF-β to drive dissemination. Metabolic reprogramming, including glycolysis-derived lactate accumulation, fatty acid and cholesterol dysregulation, and altered amino acid utilization, further constrain antitumor immunity and support angiogenesis and therapeutic resistance. This review summarizes recent advances in the bidirectional crosstalk between GC cells and key TME components, emphasizing how immune remodeling, extracellular matrix (ECM) reprogramming, and metabolic rewiring converge to sustain tumor progression, while highlighting integrative signaling networks linking immune cells, ECM, and metabolites, and providing emerging opportunities for multi-target strategies that disrupt TME-dependent metastasis.

## Linked entities

- **Genes:** PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 5290], AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207], MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475], MAPK (mitogen activated kinase-like protein) [NCBI Gene 7446652], EPHB2 (EPH receptor B2) [NCBI Gene 2048], TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040]
- **Proteins:** TBX1 (T-box transcription factor 1), ITGB1 (integrin subunit beta 1)
- **Chemicals:** lactate (PubChem CID 61503), cholesterol (PubChem CID 5997)
- **Diseases:** gastric cancer (MONDO:0001056), cancer (MONDO:0004992)

## Full-text entities

- **Genes:** AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}
- **Diseases:** metastasis (MESH:D009362), GC (MESH:D013274), cancer (MESH:D009369), hypoxia (MESH:D000860)
- **Chemicals:** fatty acid (MESH:D005227), lactate (MESH:D019344), cholesterol (MESH:D002784), amino acid (MESH:D000596)

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC13013525/full.md

---
Source: https://tomesphere.com/paper/PMC13013525